US FDA, GSK put Avandia pharmacy exit plan in place
This article was originally published in SRA
As of 18 November, GlaxoSmithKline's once-top selling Type II diabetes drug Avandia (rosiglitazone) will no longer be available in US retail pharmacies. The only access to Avandia – and to its related products Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride) – will be by mail order to patients already enrolled in a tightly controlled restricted access programme, the US Food and Drug Administration and GSK said on 18 May1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.